Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for valsartan effects on calcium handling in HFpEF models; human trials needed before any clinical consideration.
Objectives: The aim was to investigate the effects of valsartan on the sarcoplasmic reticulum Ca²⁺-ATPase pump (SERCA) and L-type Ca²⁺ channel current (ICaL) of the left ventricular myocardium in rats with heart failure with preserved ejection fraction. Methods: The 30-week-old male spontaneously hypertensive rats (SHRs) are randomly divided into the non-Valsartan and Valsartan groups, and the 30-week-old male Wistar-Kyoto rats served as control rats. The expression of SERCA is measured by Western blot. The ICaL is measured by whole-cell patch clamp. The left ventricular end-diastolic pressure and left ventricular relaxation time constant quantity are measured at the same time. Results: The left ventricular end-diastolic pressure is much higher in SHRs compared with that in control rats (p < 0.01). The left ventricular relaxation time constant quantity is markedly extended in SHRs compared with control rats (p < 0.01). Valsartan cannot increase the expression of SERCA nor decrease the density of ICaL compared with the non-Valsartan group (p > 0.05). Conclusions: Valsartan has no effect on SERCA and ICaL of the left ventricular myocardium in rats with heart failure with preserved ejection fraction.
No takes yet. Share an insight, caveat, or question.
Gui-hua et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: